Table 2 Distribution of antifungal treatment administered according to CAGTA results.
No. of patients (%) | ||||
|---|---|---|---|---|
Total | CAGTA + | CAGTA - | p value | |
Fluconazole | 13 (48.1) | 6 (60) | 7 (41.2) | 0.34 |
Voriconazole | 4 (14.8) | 3 (30) | 1 (5.9) | 0.08 |
Fluconazole + caspofungin* | 4 (14.8) | 0 | 4 (23.5) | 0.09 |
Liposomal amphotericin B | 2 (7.4) | 0 | 2 (11.8) | 0.25 |
Liposomal amphotericin B + fluconazole* | 2 (7.4) | 0 | 2 (11.8) | 0.25 |
Caspofungin | 1 (3.7) | 0 | 1 (5.8) | 0.43 |
Fluconazole + liposomal amphotericin B +caspofungin* | 1 (3.7) | 1 (10) | 0 | 0.18 |
Total | 27 (100) | 10 (100) | 17 (100) | - |